Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl methanesulfonate is an **alkylating agent** and a laboratory reagent primarily used in research and chemical mutagenesis[2]. It is a colorless to amber liquid, highly soluble in water[3][4]. As an alkylator, MMS methylates DNA bases, mainly at N7 of deoxyguanosine and N3 of deoxyadenosine, leading to DNA damage such as stalling of replication forks and production of single-strand breaks[2][5]. MMS is considered a carcinogen and suspected reproductive toxicant, and has established corrosive and irritant properties in humans[2][3]. While it is noted as being used in cancer research and as a model mutagen, its direct application in medicinal cancer treatment is extremely limited and not as an approved pharmaceutical agent for therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl methanesulfonate.